Mouse monoclonal antibodies are standard in research and diagnostic. Among all advantages of mouse monoclonal antibodies there is a lack of affinity, sensitivity and specificity especially for small epitopes and antigens that are non-immunogenic to rodents. This suggests that a huge number of diseases are under-diagnosed because of non-availability of high-quality antibodies.
Generating monoclonal antibodies from the guinea pig is a breakthrough. Moreover this cutting edge technology could rapidly take the market share of the disappointing rabbit monoclonals, featuring sometimes good affinity but often very poor productivity and being unstable.
SynAbs has therefore opted to develop its own Syn7 myeloma cell line to manufacture guinea pig monoclonal antibodies and offer more efficient investigation tools for researchers.
After a year of research, SynAbs has managed to develop a fusion cell line, called Syn7, so that guinea pig B lymphocytes can be fused efficiently to obtain hybridomas that produce monoclonal antibodies in a stable way. Around 107 splenocytes can be isolated in a guinea pig spleen, a comparable number to rats but around twice that for mice.
The Syn7 fusion rate with guinea pig splenocytes is comparable to that obtained with SP2/0 for mice or IR983 for rats, i.e. approximately 12 hybridomas per million fused splenocytes, which means that more than 1000 hybridomas can be obtained from a guinea pig spleen. After analysis, we observed that nearly 50% of the hybridomas produced an antibody, with production rates comparable to those for mice and rats.
Here are the humoral responses of a guinea pig and a rat immunized in the same way with a steroid coupled to KLH and determined by titration on the same steroid coupled to ovalbumin.
It has been observed on many occasions that the humoral response to a particular antigen was on average at least two times higher in guinea pigs than in rats or mice.